Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM3RWXL)

Drug Name
Resveratrol Drug Info
Synonyms
Resveratrol; Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4′,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
Cross-matching ID
PubChem CID
445154
ChEBI ID
CHEMBL165
CAS Number
CAS 501-36-0
TTD Drug ID
D0U3EP
VARIDT Drug ID
DR00287
INTEDE Drug ID
DR1406

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.61 0.00e+0 34/36 (94.44%) PCNA;POLE2;MCM2;...
Oxidative phosphorylation 2.34 0.00e+0 93/133 (69.92%) NDUFAB1;NDUFA8;NDUFB2;...
Pyrimidine metabolism 2.24 0.00e+0 40/56 (71.43%) TYMS;RRM2;DCTPP1;...
Mismatch repair 2.15 1.64e-3 22/23 (95.65%) PCNA;MSH2;RFC3;...
Base excision repair 2.13 1.31e-3 29/33 (87.88%) PCNA;POLE2;FEN1;...
Parkinson disease 2.12 1.09e-3 176/249 (70.68%) NDUFAB1;CYCS;VDAC3;...
Homologous recombination 2.12 9.38e-4 35/41 (85.37%) RAD51;RPA3;BRCA1;...
Proteasome 2.05 8.21e-4 44/46 (95.65%) PSMB10;PSMA1;PSMA3;...
p53 signaling pathway 2.02 7.30e-4 63/73 (86.3%) CCNE2;RRM2;CYCS;...
Thermogenesis 2.02 6.57e-4 173/232 (74.57%) NDUFAB1;ACTB;NDUFA8;...
Purine metabolism 1.91 5.97e-4 102/129 (79.07%) RRM2;ADA2;CANT1;...
Prion disease 1.89 5.47e-4 209/273 (76.56%) HSPA8;NDUFAB1;CYCS;...
Huntington disease 1.88 5.05e-4 233/306 (76.14%) NDUFAB1;CYCS;VDAC3;...
Drug metabolism 1.87 1.41e-3 78/151 (51.66%) RRM2;DUT;MGST2;...
Amyotrophic lateral sclerosis 1.85 2.19e-3 267/364 (73.35%) NEFH;NDUFAB1;CYCS;...
Glutathione metabolism 1.81 6.16e-3 43/57 (75.44%) LAP3;RRM2;GGCT;...
Nucleotide excision repair 1.79 6.57e-3 40/47 (85.11%) PCNA;POLE2;POLE3;...
Fanconi anemia pathway 1.76 8.39e-3 36/54 (66.67%) RAD51;RMI1;FANCI;...
Ribosome 1.76 7.95e-3 113/158 (71.52%) MRPL16;MRPL15;MRPS2;...
N-Glycan biosynthesis 1.74 9.85e-3 38/50 (76%) MGAT2;RPN2;ALG5;...
Cell cycle 1.69 1.63e-2 110/124 (88.71%) PCNA;CDC45;TFDP1;...
Type I diabetes mellitus 1.64 2.84e-2 38/43 (88.37%) PTPRN2;HLA-DPB1;HLA-DPA1;...
Ribosome biogenesis in eukaryotes 1.62 2.91e-2 52/108 (48.15%) POP5;POP4;IMP3;...
Complement and coagulation cascades 1.62 2.93e-2 76/85 (89.41%) C3;A2M;CLU;...
Systemic lupus erythematosus 1.61 3.23e-2 45/135 (33.33%) C3;HLA-DPB1;HLA-DPA1;...
Diabetic cardiomyopathy 1.60 3.23e-2 162/203 (79.8%) NDUFAB1;VDAC3;NDUFA8;...
Viral myocarditis 1.58 3.50e-2 53/60 (88.33%) CYCS;ITGB2;HLA-DPB1;...
Alzheimer disease 1.57 3.85e-2 279/369 (75.61%) NDUFAB1;CYCS;FZD1;...
Cysteine and methionine metabolism 1.57 3.71e-2 43/50 (86%) ENOPH1;GOT2;GOT1;...
Citrate cycle (TCA cycle) 1.56 3.85e-2 30/30 (100%) DLD;SUCLA2;SDHD;...
Endometrial cancer -1.66 4.62e-2 56/58 (96.55%) PIK3R2;BRAF;MAPK1;...
AGE-RAGE signaling pathway in diabetic complications -1.67 4.28e-2 97/100 (97%) PIK3R2;MAPK1;PLCB4;...
Renin-angiotensin system -1.68 3.84e-2 20/23 (86.96%) PRCP;ENPEP;ACE2;...
Aldosterone-regulated sodium reabsorption -1.69 3.82e-2 34/37 (91.89%) PIK3R2;MAPK1;PIK3CB;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.69 3.88e-2 79/89 (88.76%) PIK3R2;MAPK1;NFKBIA;...
Primary immunodeficiency -1.69 4.13e-2 33/38 (86.84%) IGLL1;ZAP70;RAG2;...
Adherens junction -1.72 3.75e-2 63/71 (88.73%) CSNK2A1;MAPK3;ACTN4;...
GnRH secretion -1.72 3.91e-2 60/64 (93.75%) GNRH1;CACNA1I;KCNJ3;...
ErbB signaling pathway -1.72 4.21e-2 79/85 (92.94%) PIK3R2;NRG1;BRAF;...
Parathyroid hormone synthesis, secretion and action -1.78 2.22e-2 98/106 (92.45%) GATA3;BRAF;MAPK1;...
VEGF signaling pathway -1.78 2.43e-2 50/59 (84.75%) PLA2G4C;SH2D2A;AKT2;...
MicroRNAs in cancer -1.78 2.67e-2 146/310 (47.1%) SIRT1;PIK3R2;MAPK1;...
Steroid hormone biosynthesis -1.79 2.65e-2 43/61 (70.49%) UGT2B17;SRD5A1;HSD3B1;...
Mitophagy -1.79 2.98e-2 56/68 (82.35%) RHOT2;MFN1;CALCOCO2;...
T cell receptor signaling pathway -1.80 3.01e-2 93/104 (89.42%) PIK3R2;MAPK1;NFKBIA;...
B cell receptor signaling pathway -1.81 3.28e-2 71/81 (87.65%) CD22;CD79B;PIK3R2;...
Phosphatidylinositol signaling system -1.83 3.09e-2 82/97 (84.54%) IP6K2;PIK3R2;PLCB4;...
NF-kappa B signaling pathway -1.85 3.16e-2 90/104 (86.54%) NFKBIA;LTBR;TNFSF11;...
Osteoclast differentiation -1.91 1.87e-2 117/127 (92.13%) PIK3R2;MAPK1;NFKBIA;...
TNF signaling pathway -2.03 0.00e+0 103/112 (91.96%) IL18R1;IRF1;PIK3R2;...
IL-17 signaling pathway -2.28 0.00e+0 84/94 (89.36%) MAPK1;FADD;MMP9;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 10uM 6H
Bone marrow
Neuroblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SH-SY5Y CVCL_0019 Homo sapiens 0.04uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.002uM - 25uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.04uM - 10uM 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 10uM 6H
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 10uM 6H
MDST8 CVCL_1400 Homo sapiens 10uM 6H
NCI-H508 CVCL_1561 Homo sapiens 10uM 6H
SNU-1040 CVCL_5001 Homo sapiens 10uM 6H
SNU-C4 CVCL_5008 Homo sapiens 10uM 6H
SNU-C5 CVCL_5009 Homo sapiens 10uM 6H
SW480 CVCL_0546 Homo sapiens 10uM 6H
SW620 CVCL_0547 Homo sapiens 10uM 6H
SW948 CVCL_0550 Homo sapiens 10uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 10uM 6H
HT115 CVCL_1294 Homo sapiens 10uM 6H
RKO CVCL_0504 Homo sapiens 10uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 10uM 6H
SNG-M CVCL_1707 Homo sapiens 10uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 10uM 6H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 0.04uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.002uM - 10uM 6H, 24H
A549/Asc-1 CVCL_YA87 Homo sapiens 0.04uM - 10uM 24H
DV-90 CVCL_1184 Homo sapiens 10uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 10uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 10uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 10uM 6H
T3M-10 CVCL_1729 Homo sapiens 10uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 10uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 10uM 6H
HCC515 CVCL_5134 Homo sapiens 0.002uM - 10uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 10uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 10uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 10uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 10uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 10uM 6H
OV7 CVCL_1623 Homo sapiens 10uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 10uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 10uM 6H
RMUG-S CVCL_1666 Homo sapiens 10uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 6H, 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 6H, 24H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 10uM 6H
PL-21 CVCL_2161 Homo sapiens 10uM 6H
SKM-1 CVCL_0010 Homo sapiens 10uM 6H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.002uM - 25uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
SK-L CVCL_1699 Homo sapiens 0.04uM - 10uM 24H
SK-MEL-1 CVCL_0523 Homo sapiens 10uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 10uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 10uM 6H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H